These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22237261)

  • 1. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
    Weickhardt A; Doebele R; Oton A; Lettieri J; Maxson D; Reynolds M; Brown A; Jackson MK; Dy G; Adjei A; Fetterly G; Lu X; Franklin W; Varella-Garcia M; Hirsch FR; Wynes MW; Youssoufian H; Adjei A; Camidge DR
    J Thorac Oncol; 2012 Feb; 7(2):419-26. PubMed ID: 22237261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
    Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
    Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
    Ramalingam SS; Spigel DR; Chen D; Steins MB; Engelman JA; Schneider CP; Novello S; Eberhardt WE; Crino L; Habben K; Liu L; Jänne PA; Brownstein CM; Reck M
    J Clin Oncol; 2011 Dec; 29(34):4574-80. PubMed ID: 22025157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
    Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
    Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
    Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
    J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
    El-Khoueiry AB; O'Donnell R; Semrad TJ; Mack P; Blanchard S; Bahary N; Jiang Y; Yen Y; Wright J; Chen H; Lenz HJ; Gandara DR
    Cancer Chemother Pharmacol; 2018 May; 81(5):957-963. PubMed ID: 29520435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
    Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
    Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.
    Higano CS; Berlin J; Gordon M; LoRusso P; Tang S; Dontabhaktuni A; Schwartz JD; Cosaert J; Mehnert JM
    Invest New Drugs; 2015 Apr; 33(2):450-62. PubMed ID: 25749986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
    Kubota K; Nishiwaki Y; Tamura T; Nakagawa K; Matsui K; Watanabe K; Hida T; Kawahara M; Katakami N; Takeda K; Yokoyama A; Noda K; Fukuoka M; Saijo N
    J Thorac Oncol; 2008 Dec; 3(12):1439-45. PubMed ID: 19057270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Novello S; Scagliotti G; de Castro G; Kiyik M; Kowalyszyn R; Deppermann KM; Arriola E; Bosquee L; Novosiadly RD; Nguyen TS; Forest A; Tang S; Kambhampati SRP; Cosaert J; Reck M
    J Thorac Oncol; 2017 Feb; 12(2):383-389. PubMed ID: 27464970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
    Lee JY; Sun JM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Ku BM; Koh J; Bae YH; Lee SH; Ahn JS; Park K; Ahn MJ
    Clin Cancer Res; 2016 May; 22(9):2139-45. PubMed ID: 26667485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
    Groen HJ; Socinski MA; Grossi F; Juhasz E; Gridelli C; Baas P; Butts CA; Chmielowska E; Usari T; Selaru P; Harmon C; Williams JA; Gao F; Tye L; Chao RC; Blumenschein GR
    Ann Oncol; 2013 Sep; 24(9):2382-9. PubMed ID: 23788751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
    Ranson M; Reck M; Anthoney A; Hanauske AR; Dean E; Melezinek I; Klingelschmitt G; Kletzl H; Blatter J; Twelves C
    Ann Oncol; 2010 Nov; 21(11):2233-2239. PubMed ID: 20444843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
    Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
    Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.
    Abou-Alfa GK; Capanu M; O'Reilly EM; Ma J; Chou JF; Gansukh B; Shia J; Kalin M; Katz S; Abad L; Reidy-Lagunes DL; Kelsen DP; Chen HX; Saltz LB
    J Hepatol; 2014 Feb; 60(2):319-24. PubMed ID: 24045151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Shimizu T; Yonesaka K; Hayashi H; Iwasa T; Haratani K; Yamada H; Ohwada S; Kamiyama E; Nakagawa K
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):489-495. PubMed ID: 28144730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
    Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.